Research and Markets reports that fibromyalgia is a burgeoning market that will expand with an upsurge in diagnosis and treatments following the FDA’s approval of Lyrica as a treatment.
In 2006 the market was estimated to be $367 million. They believe the market will continue to grow to $1.7 billion by 2016. The growth of the ‘fibromyalgia market’ will be spurred on by the commercial success of FDA approved drugs and will encourage other companies to invest in research and development. A defined regulatory pathway will also attract investors.